ADAM17 and cancer: However, pharmacological inhibitors of ADAM17 have advanced in specificity and progressed to clinical trials for cancer (for example, https://clinicaltrials.gov/ct2/show/record/NCT02141451), and have been reported to be well-tolerated (Friedman et al., 2009; Duffy et al., 2011).